This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Full text research articles discussing clinical or cost-effectiveness aspects of Inspiris Resilia bioprosthesis published in English were included in this analysis. Studies were excluded if they weren’t exclusively conducted on patients submitted to surgical aorticvalve replacement using the Inspiris Resilia bioprosthesis.
A significant proportion of patients with severe aortic stenosis (AS) undergoing transcatheter aorticvalve implantation (TAVI) have concomitant coronary artery disease (CAD). The best way to treat these patients is contentious.
What is the relationship between aorticvalve calcification (AVC) and aortic stenosis (AS) severity in patients with suspected low-flow low-gradient AS?
The goal of the AVATAR trial was to evaluate aorticvalve replacement (AVR) compared with conservative therapy among patients with asymptomatic severe aortic stenosis.
Transcatheter aorticvalve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aorticvalve complex. Specifically, 14.2%
The goal of the NOTION trial was to compare outcomes after transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR) in unselected patients with severe degenerative aortic stenosis.
The goal of the NOTION-3 trial was to evaluate percutaneous coronary intervention (PCI) compared with conservative therapy among patients with obstructive coronary artery disease undergoing transcatheter aorticvalve implantation (TAVI).
Transcatheter aorticvalve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.
The following are key points to remember from a state-of-the-art review on sutureless valves, a “wireless†option for patients with aorticvalve disease.
How do mortality and morbidity compare after valve-in-valve (ViV) transcatheter aorticvalve replacement (TAVR) versus redo surgical aorticvalve replacement (SAVR) for intervention for a failed bioprosthetic SAVR?
Blaha, MD, MPH discuss Prevalence of AorticValve Calcium and the Long-Term Risk of Incident Severe Aortic Stenosis. In this interview, Richard A. Chazal MD, MACC and Michael J.
The goal of the DEDICATE-DZHK6 trial was to evaluate transcatheter aorticvalve implantation (TAVI) compared with surgical aorticvalve replacement (SAVR) among patients with severe aortic stenosis and low to intermediate surgical risk.
The goal of the VIVA trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with surgical aorticvalve replacement (SAVR) among patients with severe aortic stenosis and a small aortic annulus.
What is the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR)?
Articles were analyzed with bibliometric tools such as CiteSpace and VOSviewer to identify key research trends, core authors, institutions, and research hotspots in AI applications for AVS.ResultsA total of 118 articles were analyzed, showing a significant increase in publications from 2014 onwards.
The goal of the BICATOR trial was to determine whether treatment with low to moderate dose atorvastatin is associated with progression of ascending aortic dilation, valvular dysfunction, or valve calcification in patients with bicuspid aorticvalve.
The optimal management of concomitant chronic obstructive coronary artery disease (CAD) in transcatheter aorticvalve replacement (TAVR) recipients remains a debated topic. Original article: Persits I et al. While some advocate for pre-TAVR percutaneous coronary intervention, others adopt an expectant approach.
The goal of the TAVR UNLOAD trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with chronic systolic heart failure and moderate aortic stenosis (stage B aortic stenosis).
The goal of the POPular PAUSE TAVI trial was to determine whether, in patients undergoing transcatheter aorticvalve implantation (TAVI) who also take oral anticoagulation for a comorbid condition, continuation of anticoagulant therapy is noninferior to periprocedural interruption of anticoagulation with respect to major adverse cardiovascular and (..)
What are the hemodynamic and clinical outcomes after transcatheter aorticvalve replacement (TAVR) and surgical aorticvalve replacement (SAVR) among patients with severe aortic stenosis (AS) and a small aortic annulus?
The goal of the EARLY TAVR trial was to evaluate transcatheter aorticvalve replacement (TAVR) compared with clinical surveillance among patients with asymptomatic severe aortic stenosis (stage C aortic stenosis).
ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The use of transcatheter aorticvalve replacement (TAVR) has become the preferred therapy for most patients with AS and concomitant HF.
This concept should be applied when managing older patients with severe aortic stenosis. Although left ventricular wall hypertrophy is expected in patients with aortic stenosis, it should not be assumed that this is caused only by aortic stenosis.
Heterogeneity was assessed using I2 statistics. All statistical analyses were conducted using Review Manager (Rev Man, Version 5.4; The Cochrane Collaboration, Copenhagen, Denmark).Results:After to 1.17, p=0.30, I2 3%).
The goal of the SOLVE-TAVI trial was to compare the safety and efficacy of the Edwards Sapien S3 valve vs. Medtronics CoreValve among patients undergoing transcatheter aorticvalve replacement (TAVR) for severe aortic stenosis.
Patients with bicuspid aorticvalves (BAV) are predisposed to the development of aortic stenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR) in patients with BAV. to 4.58, p=0.04).
A 76-year-old woman with a history of double valve replacement (Aortic and mitral valves) for rheumatic heart disease, presented with acute dyspnea after a switch from Warfarin to LMWH before a planned bone marrow biopsy. Hence distal protection by an Aortic sentinel device or its equivalent (FilterWire EZ, Tri-guard) is a must.
The goal of the TCW trial was to test the noninferiority and, if positive, superiority, of percutaneous coronary intervention (PCI) with transcatheter aorticvalve implantation (TAVI) compared with surgical aorticvalve replacement (SAVR) and coronary artery bypass grafting (CABG) in severe aortic stenosis (AS) with comorbid coronary artery disease (..)
What are clinical outcomes among patients with severe aortic stenosis (AS) and coronary artery disease (CAD) undergoing surgical aorticvalve replacement (SAVR) plus revascularization versus transcatheter aorticvalve replacement (TAVR) plus percutaneous coronary intervention (PCI)?
The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.
Mechanical surgical aorticvalve replacement (AVR) was associated with lower all-cause mortality in patients 60 years old compared with bioprosthetic AVR, according to a study on the longitudinal survival difference among more than 100,000 patients presented at the Society of Thoracic Surgeons (STS) Annual Meeting.
For the treatment of transcatheter aorticvalve (TAV) thrombosis, both in its more common form of subclinical leaflet thrombosis (SLT) and the rarer clinical valve thrombosis (CVT), pharmacotherapy with vitamin K antagonists (VKA), non-vitamin K oral anticoagulants (NOAC) and an ultraslow, low-dose infusion of thrombolytics should be considered as (..)
In these panel discussions, host Andrea Price, MS, AACC brings together Marian Hawkey, RN and Misty Theriot, BSN to explore best practices related to structural heart disease.
The following are key points to remember from a state-of-the-art guide to transcatheter aorticvalve (TAV) design and systematic planning for a redo-TAV (TAV-in-TAV) procedure.
The goal of the EVOLVED trial was to assess the safety and efficacy of early aorticvalve replacement compared with conservative management among patients with asymptomatic severe aortic stenosis, normal ejection fraction (EF), and presence of myocardial fibrosis on cardiac magnetic resonance imaging (CMR).
In a cohort of patients with severe aortic stenosis (AS) who underwent aorticvalve replacement (AVR), the degree of myocardial fibrosis provides significant prognostic information in women and men.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content